Literature DB >> 2900293

Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa.

R J Hardie1, A J Lees.   

Abstract

Twenty six consecutive patients with neuroleptic-induced Parkinson's syndrome (NIPS) are described. Their median age was 61 years, 60% were female, and most had received chronic neuroleptic medication for psychiatric indications. The clinical features were indistinguishable from idiopathic Parkinson's disease, except for the presence of co-existing orofacial chorea, limb dyskinesia or akathisia which provided an aetiological clue in 11 cases. Complete resolution of NIPS occurred in only two patients, one of whom later developed Parkinson's disease. Sixteen patients were treated with 300-1000 mg levodopa/benserazide for up to 4 years with few adverse effects but therapeutic response was disappointing.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2900293      PMCID: PMC1033159          DOI: 10.1136/jnnp.51.6.850

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  35 in total

1.  Assessment of drugs in schizophrenia. Discussion on assessment of drug-induced extrapyramidal reactions.

Authors:  H A McClelland
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

2.  Psychomotility and parkinsonism in treatment with neuroleptic drugs.

Authors:  F A FREYHAN
Journal:  AMA Arch Neurol Psychiatry       Date:  1957-11

3.  L-dopa in depressed patients.

Authors:  W E Bunney; D L Murphy; H K Brodie; F K Goodwin
Journal:  Lancet       Date:  1970-02-14       Impact factor: 79.321

4.  Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms.

Authors:  G Chouinard; L Annable; P Mercier; L Turnier
Journal:  Psychopharmacol Bull       Date:  1987

Review 5.  Assessment of extrapyramidal disorders.

Authors:  C D Marsden; M Schachter
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

6.  The motor disorders of severe psychiatric illness: a conflict of paradigms.

Authors:  D Rogers
Journal:  Br J Psychiatry       Date:  1985-09       Impact factor: 9.319

7.  Reversible drug-induced parkinsonism. Clinicopathologic study of two cases.

Authors:  A H Rajput; B Rozdilsky; O Hornykiewicz; K Shannak; T Lee; P Seeman
Journal:  Arch Neurol       Date:  1982-10

8.  Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry.

Authors:  S R Hirsch; R Gaind; P D Rohde; B C Stevens; J K Wing
Journal:  Br Med J       Date:  1973-03-17

9.  Drug-induced parkinsonism in the elderly.

Authors:  P J Stephen; J Williamson
Journal:  Lancet       Date:  1984-11-10       Impact factor: 79.321

10.  Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine.

Authors:  C Chouza; A Scaramelli; J L Caamaño; O De Medina; R Aljanati; S Romero
Journal:  Lancet       Date:  1986-06-07       Impact factor: 79.321

View more
  32 in total

1.  Graves' disease presenting as hemiparkinsonism.

Authors:  J S Davies; P K Morrish; M F Scanlon
Journal:  J Endocrinol Invest       Date:  2001-03       Impact factor: 4.256

2.  Co-occurrence of parkinsonism and dementia in clinical practice: relevant differential diagnoses.

Authors:  I Liepelt-Scarfone; M Jamour; W Maetzler
Journal:  Z Gerontol Geriatr       Date:  2012-01       Impact factor: 1.281

3.  Drug-induced parkinsonism.

Authors:  Frandy Susatia; Hubert H Fernandez
Journal:  Curr Treat Options Neurol       Date:  2009-05       Impact factor: 3.598

4.  Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism.

Authors:  P H Lee; J S Kim; D H Shin; S-N Yoon; K Huh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-08-15       Impact factor: 10.154

5.  Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.

Authors:  A Dalvi; B Ford
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

6.  Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate.

Authors:  T M Hyde; M F Egan; L L Wing; R J Wyatt; D R Weinberger; J E Kleinman
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

7.  A magneto-inductive sensor based wireless tongue-computer interface.

Authors:  Xueliang Huo; Jia Wang; Maysam Ghovanloo
Journal:  IEEE Trans Neural Syst Rehabil Eng       Date:  2008-10       Impact factor: 3.802

Review 8.  Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly.

Authors:  Carlos Estevez-Fraga; Paul Zeun; Jose Luis López-Sendón Moreno
Journal:  Drugs Aging       Date:  2018-11       Impact factor: 3.923

9.  Microstructural white matter alterations in patients with drug induced parkinsonism.

Authors:  Yoonju Lee; Yong Ho Choi; Jae Jung Lee; Hye Sun Lee; Young H Sohn; Jong-Min Lee; Phil Hyu Lee
Journal:  Hum Brain Mapp       Date:  2017-09-12       Impact factor: 5.038

10.  Clinical Implications of Cardiac-MIBG SPECT in the Differentiation of Parkinsonian Syndromes.

Authors:  Dong Hoon Shin; Phil Hyu Lee; Oh Young Bang; In Soo Joo; Kyoon Huh
Journal:  J Clin Neurol       Date:  2006-03-20       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.